JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Jazz Pharmaceuticals PLC

Closed

SectorHealthcare

110.76 -0.45

Overview

Share price change

24h

Current

Min

110.04

Max

113.13

Key metrics

By Trading Economics

Income

-284M

-93M

Sales

-190M

898M

P/E

Sector Avg

15.775

34.393

Profit margin

-10.307

Employees

2,800

EBITDA

-275M

109M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+61.9% upside

Market Stats

By TradingEconomics

Market Cap

-374M

7B

Previous open

111.21

Previous close

110.76

News Sentiment

By Acuity

67%

33%

332 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Jazz Pharmaceuticals PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 lis 2024, 14:45 UTC

Major Market Movers

Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK

31 paź 2024, 15:29 UTC

Major Market Movers

Avadel Pharma Shares Rise on Favorable Ruling for FDA in Lumryz Litigation

Peer Comparison

Price change

Jazz Pharmaceuticals PLC Forecast

Price Target

By TipRanks

61.9% upside

12 Months Forecast

Average 180.2 USD  61.9%

High 230 USD

Low 123 USD

Based on 16 Wall Street analysts offering 12 month price targets forJazz Pharmaceuticals PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

14

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

N/A / 111.22Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

332 / 374 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$